Quick Summary — TGTX scores higher on quality with 8.6/10 vs TCRX's 6.4/10. TCRX trades at $0.98 while TGTX trades at $36.64. Both analyzed daily using SEC EDGAR data across 13 institutional models.
TGTX scores higher with a 8.6/10 quality rating vs TCRX's 6.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $0.98, TCRX trades +32.0% above its Bayesian DCF fair value of $0.67, while TGTX at $36.64 trades +57.5% above its estimate of $15.58. TGTX shows a wider gap between price and intrinsic value.
TCRX earns a Quality of Company score of 6.4/10 compared to TGTX's 8.6/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
TCRX carries a SAFE value trap risk (24/100) while TGTX shows SAFE risk (6/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both TCRX and TGTX operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare TCRX vs TGTX differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.